11Sep 2023
The tissue‐specific metabolic effects of the PPARα agonist ciprofibrate in insulin‐resistant male individuals

The tissue‐specific metabolic effects of the PPARα agonist ciprofibrate in insulin‐resistant male individuals

The study assessed the potential effects of the peroxisome proliferator‐activated receptor‐α (PPARα) agonist ciprofibrate on cardiac and hepatic metabolism in insulin-resistant volunteers. Ten male participants underwent a randomized, double-blind crossover trial, receiving 100 mg/d of ciprofibrate or a placebo for 5 weeks. The results showed that ciprofibrate treatment increased hepatic lipid accumulation and reduced insulin-stimulated hepatic glucose metabolism. However, it did not significantly affect overall insulin sensitivity, cardiac function, or cardiac energy status. Furthermore, skeletal muscle gene expression remained unchanged.

  • #endo-diabetology

Like

Save

Share